Business Wire | Jul 16, 2020 07:00AM EDT

AngioDynamics Reports Fiscal 2020 Fourth Quarter and Full-Year Financial Results

Jul. 16, 2020

LATHAM, N.Y.--(BUSINESS WIRE)--Jul. 16, 2020--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the fourth quarter of fiscal year 2020, which ended May 31, 2020.

"Our fourth quarter sales were impacted by the deferral of elective procedures associated with COVID-19, and we adjusted accordingly throughout the quarter to minimize the impact of the global pandemic on our business," commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. "Despite these temporary challenges, the underlying long-term fundamentals of our business remain intact, and we intend to continue investing strategically in our key growth platforms like Auryon, NanoKnife, and AngioVac. The steps that we took to manage the business through the end of the year will enable us to resume growth and improve our profitability as the environment eventually normalizes. While much of our near-term attention has been on managing through the impacts of COVID-19, we remain focused on our long-term strategy and the transformation of AngioDynamics into a Company with differentiated technology platforms that compete in larger, higher-growth addressable markets."

Fourth Quarter 2020 Financial Results

Net sales for the fourth quarter of fiscal 2020 were $58.3 million, a decrease of 18.1% compared to the prior-year quarter. Excluding the impact of Asclera sales, which were discontinued during fiscal year 2019, net sales decreased 16.8% year over year. Net sales were impacted across the board by the disruption to procedure volumes resulting from the COVID-19 global pandemic. Foreign currency translation did not have a significant impact on the Company's sales in the quarter.

* Oncology net sales were $12.5 million, a decrease of 18.0% from $15.3 million a year ago, with growth in NanoKnife capital sales more than offset by declines across the rest of the Oncology portfolio. * Vascular Interventions and Therapies ("VIT") net sales were $22.1 million, a decrease of 28.8%, compared to $31.0 million a year ago. Excluding last year's Asclera sales of $1.1 million in the fourth quarter, VIT declined 26.2%. * Vascular Access net sales were $23.7 million, a decrease of 4.6% from $24.9 million a year ago.

Excluding Asclera, U.S. net sales in the fourth quarter of fiscal 2020 were $44.6 million, a decrease of 18.4% from $54.7 million a year ago, and International net sales were $13.7 million, a decrease of 10.9% from $15.4 million a year ago.

Gross margin for the fourth quarter of fiscal 2020 was 51.8%, a decline of 630 basis points compared to the fourth quarter of fiscal 2019. The gross margin decline was primarily attributable to under absorption in manufacturing operations, as the Company maintained staffing levels and continued producing product in the plant to provide flexibility during the severe uncertainty brought about by the COVID-19 global pandemic during the fourth quarter. The Company expects this under absorption to continue through the first half of fiscal 2021 as it continues to assess the shape and timing of the COVID-19 recovery. In addition, gross margin during the fourth quarter was negatively impacted by 160 basis points due to a write off of raw materials and existing dosimetry inventory associated with OARtrac that was purchased pursuant to the Company's acquisition of RadiaDyne. These inventory items were deemed unmarketable absent subsequent design and development activities. This inventory write down has been excluded from the Company's adjusted earnings per share and adjusted EBITDA.

The Company recorded a net loss from continuing operations of $156.1 million, or loss per share of $4.10, in the fourth quarter of fiscal 2020. This compares to net income from continuing operations of approximately $2.8 million, or earnings per share of $0.07, a year ago. Net income from continuing operations and GAAP earnings per share were negatively impacted by a goodwill impairment described in more detail below. Excluding this impairment, net income from operations and earnings per share in the fourth quarter of fiscal 2020 would have been $1.5 million and $0.04, respectively.

Excluding the items shown in the non-GAAP reconciliation table below, adjusted net loss for the fourth quarter of fiscal 2020 was $2.1 million, or a loss of $0.06 per share, compared to adjusted net income of $2.8 million, or earnings per share of $0.07, in the fourth quarter of fiscal 2019.

Adjusted EBITDA in the fourth quarter of fiscal 2020, excluding the items shown in the reconciliation table below, was $0.6 million, compared to $8.5 million in the fourth quarter of fiscal 2019.

In the fourth quarter of fiscal 2020, the Company generated $3.9 million in operating cash and had capital expenditures of $1.5 million. As of May 31, 2020, the Company had $54.4 million in cash and cash equivalents compared to $52.2 million in cash and cash equivalents at the end of the third quarter. This ending balance accounts for $27.2 million in cash and equivalents on February 29, 2020 plus the subsequent $25.0 million draw on the Company's revolver. As of May 31, 2020, the Company had $40.0 million in debt outstanding, compared to $15.0 million in debt outstanding on February 29, 2020. Management remains focused on cash preservation amid the current environment.

Full-Year 2020 Financial Results

For the twelve months ended May 31, 2020:

* Net sales were $264.2 million, a decrease of 2.4%, compared to $270.6 million for the same period a year ago. Excluding the impact of Asclera, sales of which were discontinued during fiscal year 2019, net sales were flat year over year. * The Company's net loss from continuing operations was $165.8 million, or a loss of $4.37 per share, compared to a net loss from continuing operations of $11.1 million, or a loss per share of $0.30 per share, a year ago. Net loss from continuing operations and GAAP loss per share were negatively impacted by the goodwill impairment described in more detail below. In addition to the goodwill impairment, the net loss is largely attributable to the decline in the volume of elective surgeries as well as ongoing investment in key technology platforms such as Auryon, NanoKnife, and AngioVac. Excluding this impairment, net loss from operations and loss per share in fiscal 2020 would have been $8.2 million and $0.22, respectively. * Gross margin declined 70 basis points to 56.9% from 57.6% a year ago. In addition, gross margin during fiscal year 2020 was negatively impacted by 40 basis points due to the write off of raw materials described above. * Excluding the items shown in the non-GAAP reconciliation table below, adjusted net income was $3.5 million, or $0.09 per share, compared to adjusted net income of $8.2 million, or $0.22 per share, a year ago. * Adjusted EBITDA, excluding the items shown in the reconciliation table below, was $18.0 million, compared to $30.6 million for the same period a year ago.

Goodwill Impairment

As noted above, the Company recorded a goodwill impairment for the quarter and fiscal year ended May 31, 2020. At May 31, 2020, the Company identified a triggering event resulting from the Company's market capitalization being below its book value of equity for a sustained period of time. Following the triggering event at May 31, 2020, the Company determined its fair value using a combination of the income approach and market approach. This valuation assessment indicated that the Company's book value exceeded its fair value, resulting in an impairment of goodwill of $157.6 million. The continuing uncertainty created by the COVID-19 global pandemic and associated lower procedural volumes negatively impacted the Company's fair value.

Fiscal Year 2021 Financial Guidance

The Company saw signs of a recovery throughout the fourth quarter of fiscal 2020; however, given the current trajectory of COVID-19 cases and the uncertainty surrounding the magnitude and duration of the continuing impacts of the pandemic, management will not be providing financial guidance for fiscal 2021 at this point in time.

Conference Call

The Company's management will host a conference call today at 8:00 a.m. ET to discuss its fiscal 2020 fourth quarter and full-year results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13705722.

This conference call will also be webcast and can be accessed from the "Investors" section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 11:00 a.m. ET on Thursday, July 16, 2020, until 11:59 p.m. ET on Thursday, July 23, 2020. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13705722.

Use of Non-GAAP Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported adjusted EBITDA, adjusted net income before goodwill impairment, adjusted earnings per share before goodwill impairment, adjusted net income, adjusted earnings per share, free cash flow and net sales excluding Asclera. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

About AngioDynamics, Inc.

AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. For more information, visit www.angiodynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2019 and its Quarterly Report on Form 10-Q for the period ended February 29, 2020. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue and is similarly approved for commercialization in Canada, the European Union, and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.

ANGIODYNAMICS, INC. AND SUBSIDIARIESCONSOLIDATED INCOME STATEMENTS(in thousands, except per share data)

Three months ended Twelve months ended

May 31, 2020 May 31, May 31, 2020 May 31, 2019 2019

(unaudited) (unaudited) (audited)



Net sales $ 58,332 $ 71,182 $ 264,157 $ 270,634

Cost of sales(exclusive of 28,120 29,851 113,885 114,634 intangibleamortization)

Gross profit 30,212 41,331 150,272 156,000

% of net sales 51.8 % 58.1 % 56.9 % 57.6 %



Operating expenses

Research and 7,232 6,892 29,682 28,258 development

Sales and marketing 18,207 20,775 78,634 76,829

General and 8,221 8,488 37,872 34,902 administrative

Amortization of 4,704 4,457 18,121 17,056 intangibles

Goodwill impairment 157,578 - 157,578 -

Change in fair value ofcontingent (11,647 ) (7,641 ) (11,531 ) (6,776 )consideration

Acquisition,restructuring and other 1,528 5,427 6,014 15,127 items, net

Total operating 185,823 38,398 316,370 165,396 expenses

Operating income (loss) (155,611 ) 2,933 (166,098 ) (9,396 )

Interest expense, net (235 ) (1,410 ) (907 ) (5,099 )

Other expense, net (63 ) (135 ) (130 ) (207 )

Total other expense, (298 ) (1,545 ) (1,037 ) (5,306 )net

Income (loss) fromcontinuing operations (155,909 ) 1,388 (167,135 ) (14,702 )before income taxbenefit

Income tax expense 158 (1,365 ) (1,348 ) (3,556 )(benefit)

Net income (loss) from (156,067 ) 2,753 (165,787 ) (11,146 )continuing operations

Income fromdiscontinued - 56,120 - 72,486 operations, net ofincome tax

Net income (loss) $ (156,067 ) $ 58,873 $ (165,787 ) $ 61,340



Income (loss) per share - continuing operations

Basic $ (4.10 ) $ 0.07 $ (4.37 ) $ (0.30 )

Diluted $ (4.10 ) $ 0.07 $ (4.37 ) $ (0.30 )

Income per share - discontinued operations

Basic $ - $ 1.50 $ - $ 1.93

Diluted $ - $ 1.50 $ - $ 1.93

Income (loss) per share

Basic $ (4.10 ) $ 1.57 $ (4.37 ) $ 1.64

Diluted $ (4.10 ) $ 1.57 $ (4.37 ) $ 1.64



Weighted average shares outstanding

Basic 38,072 37,485 37,961 37,485

Diluted 38,072 37,485 37,961 37,485

ANGIODYNAMICS, INC. AND SUBSIDIARIESGAAP TO NON-GAAP RECONCILIATION(in thousands, except per share data)

Reconciliation of Net Income (Loss) to non-GAAP Adjusted Net Income (Loss)Before Goodwill Impairment*:



Three months ended Twelve months ended

May 31, 2020 May 31, May 31, 2020 May 31, 2019 2019

(unaudited) (unaudited)



Net income (loss) from $ (156,067 ) $ 2,753 $ (165,787 ) $ (11,146 )continuing operations

Goodwill impairment 157,578 - 157,578 -

Net income (loss)adjusted for goodwill $ 1,511 $ 2,753 $ (8,209 ) $ (11,146 )impairment*



Reconciliation of Diluted Income (Loss) Per Share to non-GAAP Adjusted DilutedEarnings Per Share Before Goodwill Impairment*:



Three months ended Twelve months ended

May 31, 2020 May 31, May 31, 2020 May 31, 2019 2019

(unaudited) (unaudited)



Diluted earnings (loss)per share from continuing $ (4.10 ) $ 0.07 $ (4.37 ) $ (0.30 )operations

Goodwill impairment 4.14 - 4.15 -

Diluted earnings (loss)per share adjusted for $ 0.04 $ 0.07 $ (0.22 ) $ (0.30 )goodwill impairment*



Adjusted diluted 38,072 38,285 38,105 38,147 sharecount



*This does not include the Company's customary adjustments included on the nextpage.



ANGIODYNAMICS, INC. AND SUBSIDIARIESGAAP TO NON-GAAP RECONCILIATION(in thousands, except per share data)

Reconciliation of Net Income (Loss) to non-GAAP Adjusted Net Income (Loss):



Three months ended Twelve months ended

May 31, 2020 May 31, May 31, 2020 May 31, 2019 2019

(unaudited) (unaudited)



Net income (loss) from $ (156,067 ) $ 2,753 $ (165,787 ) $ (11,146 )continuing operations



Amortization of 4,704 4,457 18,121 17,056 intangibles

Goodwill impairment 157,578 - 157,578 -

Change in fair value ofcontingent (11,647 ) (7,641 ) (11,531 ) (6,776 )consideration

Dosimetry inventory 958 - 958 - write-off ^(1)

Acquisition,restructuring and other 1,528 5,427 6,014 15,127 items, net ^(2)

Write-off of deferred - - 593 - financing fees ^(3)

Tax effect of non-GAAP 799 (2,200 ) (2,406 ) (6,018 )items ^(4)

Adjusted net income $ (2,147 ) $ 2,796 $ 3,540 $ 8,243 (loss)



Reconciliation of Diluted Income (Loss) Per Share to non-GAAP Adjusted DilutedEarnings (Loss) Per Share:



Three months ended Twelve months ended

May 31, 2020 May 31, May 31, 2020 May 31, 2019 2019

(unaudited) (unaudited)



Diluted earnings (loss)per share from $ (4.10 ) $ 0.07 $ (4.37 ) $ (0.30 )continuing operations



Amortization of 0.12 0.12 0.48 0.45 intangibles

Goodwill impairment 4.14 - 4.14 -

Change in fair value ofcontingent (0.31 ) (0.20 ) (0.30 ) (0.18 )consideration

Dosimetry inventory 0.03 - 0.03 - write-off ^(1)

Acquisition,restructuring and other 0.04 0.14 0.16 0.40 items, net ^(2)

Write-off of deferred - - 0.02 - financing fees ^(3)

Tax effect of non-GAAP 0.02 (0.06 ) (0.07 ) (0.15 )items ^(4)

Adjusted dilutedearnings (loss) per $ (0.06 ) $ 0.07 $ 0.09 $ 0.22 share



Adjusted diluted 38,072 38,285 38,105 38,147 sharecount

(1) Write-off of raw materials and existing dosimetry inventory associated with OARtrac that was purchased pursuant to the Company's acquisition of RadiaDyne. These inventory items were deemed unmarketable absent subsequent design and development activities. (2) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items. (3) Deferred financing fees related to the old credit agreement were written off during the first quarter of fiscal year 2020. (4) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax rate of 23% for May 31, 2020 and May 31, 2019.

ANGIODYNAMICS, INC. AND SUBSIDIARIESGAAP TO NON-GAAP RECONCILIATION (Continued)(in thousands, except per share data)

Reconciliation of Net Income (Loss) to Adjusted EBITDA:



Three months ended Twelve months ended

May 31, 2020 May 31, May 31, 2020 May 31, 2019 2019

(unaudited) (unaudited)



Net income (loss) from $ (156,067 ) $ 2,753 $ (165,787 ) $ (11,146 )continuing operations



Income tax expense 158 (1,365 ) (1,348 ) (3,556 )(benefit)

Interest expense, net 235 1,410 907 5,099

Depreciation and 6,216 5,830 23,650 22,597 amortization

Goodwill impairment 157,578 - 157,578 -

Change in fair value ofcontingent (11,647 ) (7,641 ) (11,531 ) (6,776 )consideration

Stock based 1,594 2,122 7,592 9,218 compensation

Dosimetry inventory 958 - 958 - write-off ^(1)

Acquisition,restructuring and other 1,528 5,427 6,014 15,127 items, net ^(2)

Adjusted EBITDA $ 553 $ 8,536 $ 18,033 $ 30,563



Per diluted share:

Adjusted EBITDA $ 0.01 $ 0.22 $ 0.47 $ 0.80

(1) Write-off of raw materials and existing dosimetry inventory associated with OARtrac that was purchased pursuant to the Company's acquisition of RadiaDyne. These inventory items were deemed unmarketable absent subsequent design and development activities. (2) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

ANGIODYNAMICS, INC. AND SUBSIDIARIESNET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY(in thousands)

Three months ended Twelve months ended

May 31, May 31, % Currency Constant May 31, May 31, % Currency Constant 2020 2019 Growth Impact Currency 2020 2019 Growth Impact Currency Growth Growth

(unaudited) (unaudited)

Net Sales byProduct Category

VascularInterventions $ 22,090 $ 31,030 (28.8 ) $ 112,706 $ 119,901 (6.0 ) & % %Therapies

Vascular 23,714 24,869 (4.6 ) 94,299 94,730 (0.5 ) Access % %

Oncology 12,528 15,283 (18.0 ) 57,152 56,003 2.1 % %

$ 58,332 $ 71,182 (18.1 ) 0.0 % (17.8 )% $ 264,157 $ 270,634 (2.4 ) 0.0 % (2.2 )% % %

- -



Net Sales by Geography

United States $ 44,599 $ 55,761 (20.0 ) 0.0 % (20.0 )% $ 207,980 $ 216,957 (4.1 ) 0.0 % (4.1 )% % %

International 13,733 15,421 (10.9 ) 1.0 % (10.0 )% 56,177 53,677 4.7 % 1.0 % 5.5 % %

$ 58,332 $ 71,182 (18.1 ) 0.0 % (17.8 )% $ 264,157 $ 270,634 (2.4 ) 0.0 % (2.2 )% % %

ANGIODYNAMICS, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(in thousands)

May 31, 2020 May 31, 2019

(unaudited) (audited)

Assets

Current assets:

Cash and cash equivalents $ 54,435 $ 227,641

Accounts receivable, net 31,263 43,577

Inventories 59,905 40,071

Prepaid expenses and other 7,310 4,003

Total current assets 152,913 315,292

Property, plant and equipment, net 28,312 24,258

Other assets 15,636 3,835

Intangible assets, net 197,136 145,387

Goodwill 201,515 347,666

Total assets $ 595,512 $ 836,438

Liabilities and stockholders' equity

Current liabilities:

Accounts payable $ 19,096 $ 22,829

Accrued liabilities 29,469 38,338

Current portion of long-term debt - 7,500

Current portion of contingent consideration 836 4,635

Other current liabilities 2,133 -

Total current liabilities 51,534 73,302

Long-term debt, net of current portion 40,000 124,407

Contingent consideration, net of current portion 14,811 8,851

Deferred income taxes 24,057 14,542

Other long-term liabilities 9,238 521

Total liabilities 139,640 221,623

Stockholders' equity 455,872 614,815

Total Liabilities and Stockholders' Equity $ 595,512 $ 836,438



ANGIODYNAMICS, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)

Three months ended Twelve months ended

May 31, 2020 May 31, May 31, 2020 May 31, 2019 2019

(unaudited) (unaudited) (audited)

Cash flows from operating activities:

Net income (loss) $ (156,067 ) $ 58,873 $ (165,787 ) $ 61,340

Adjustments to reconcile net income (loss) to net cash provided by (used in)operating activities:

Depreciation and 6,255 6,722 23,805 25,880 amortization

Non-cash lease expense 503 - 2,070 -

Goodwill impairment 157,578 - 157,578 -

Gain on disposition - (46,592 ) - (46,592 )

Transaction costs for - (4,030 ) - (4,030 )disposition

Stock based 1,594 2,130 7,592 9,249 compensation

Change in fair valueof contingent (11,647 ) (7,641 ) (11,531 ) (6,776 )consideration

Deferred income taxes 38 (3,288 ) (1,568 ) (2,655 )

Change in accounts 243 (103 ) 429 (202 )receivable allowances

Fixed and intangibleasset impairments and 333 1,806 728 2,495 disposals

Write-off of other - - 593 - assets

Other 16 - 86 (5 )

Changes in operatingassets and liabilities, net ofacquisitions:

Accounts receivable 4,084 676 11,918 (3,177 )

Inventories (4,809 ) 1,274 (18,845 ) (1,428 )

Prepaid expenses and 2,925 (363 ) (6,453 ) (1,871 )other

Accounts payable,accrued and other 2,834 15,548 (15,169 ) 5,212 liabilities

Net cash provided by(used in) operating 3,880 25,012 (14,554 ) 37,440 activities

Cash flows from investing activities:

Additions to property, (1,479 ) (815 ) (7,235 ) (3,118 )plant and equipment

Acquisition of - - (350 ) - intangibles

Cash paid in - - (55,760 ) (84,920 )acquisition

Proceeds fromdisposition of - 169,242 - 169,242 discontinuedoperations

Proceeds from sale of - - - 1,350 marketable securities

Net cash provided by(used in) investing (1,479 ) 168,427 (63,345 ) 82,554 activities

Cash flows from financing activities:

Proceeds fromborrowing on revolving 25,000 - 40,000 55,000 credit facility

Repayment of long-term - (1,250 ) (132,500 ) (15,000 )debt

Deferred financingcosts on long-term - - (775 ) - debt

Payment of acquisitionrelated contingent - (6,000 ) (1,208 ) (8,100 )consideration

Proceeds (outlays)from exercise of stock (53 ) 8 (759 ) 2,031 options and employeestock purchase plan

Net cash provided by(used in) financing 24,947 (7,242 ) (95,242 ) 33,931 activities

Effect of exchangerate changes on cash (73 ) (260 ) (65 ) (380 )and cash equivalents

Increase (decrease) incash and cash 27,275 185,937 (173,206 ) 153,545 equivalents

Cash and cashequivalents at 27,160 41,704 227,641 74,096 beginning of period

Cash and cashequivalents at end of $ 54,435 $ 227,641 $ 54,435 $ 227,641period

ANGIODYNAMICS, INC. AND SUBSIDIARIESGAAP TO NON-GAAP RECONCILIATION(in thousands)

Reconciliation of Free Cash Flows:

Three months ended Twelve months ended

May 31, May 31, May 31, May 31, 2020 2019 2020 2019

(unaudited) (unaudited)



Net cash (used in) provided $ 3,880 $ 25,012 $ (14,554 ) $ 37,440 by operating activities

Additions to property, plant (1,479 ) (815 ) (7,235 ) (3,118 )and equipment

Free Cash Flow $ 2,401 $ 24,197 $ (21,789 ) $ 34,322

View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005289/en/

CONTACT: Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408